Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.47 USD | +0.87% | +30.82% | +33.07% |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 08 | Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.07% | 2.31B | C | ||
-1.29% | 12.64B | B+ | ||
-0.47% | 8.46B | B- | ||
+22.61% | 5.27B | C | ||
-2.03% | 4.49B | C | ||
-53.56% | 3.11B | D+ | ||
+19.30% | 2.87B | - | - | |
-8.42% | 2.23B | B- | ||
-3.55% | 1.89B | D+ | ||
+5.37% | 1.64B | - | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.